<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024595</url>
  </required_header>
  <id_info>
    <org_study_id>ISS OBS T-001</org_study_id>
    <nct_id>NCT01024595</nct_id>
  </id_info>
  <brief_title>Observational Study of the Therapeutic Study of Recombinant HIV-1 TAT</brief_title>
  <acronym>ISS OBS T-001</acronym>
  <official_title>Observational Study of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in Hiv-1 Infected Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Superiore di Sanità</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat (ISS
      P-001 and ISS T-001) indicate that the vaccine based on the recombinant Tat protein is safe,
      well tolerated and immunogenic. The present study is intended to extend the follow-up of the
      volunteers for additional 3 years to evaluate the persistence of the anti-Tat humoral and
      cellular immune responses. The results of the present study will be key for the design of
      future phase II trials, particularly for the definition of the optimal schedule for boosting
      immunizations.

      All individuals (27) will be enrolled in a 120-weeks observational study and monitored every
      24 weeks for the following 3 years. During these visits, which are performed within the
      schedule indicated for the clinical monitoring of HIV-1 infected individuals, in addition to
      the routine virological, hematological and biochemical assessment, the anti-Tat specific
      humoral and cellular immune responses will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the persistence of specific immune responses, volunteers will be monitored for anti-Tat specific antibodies, anti-Tat proliferative response and in vitro γIFN and IL-4 production in response to Tat (Elispot).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To develop test procedures in order to evaluate humoral and cellular anti-Tat immunity for future efficacy trials.</measure>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Without treatment</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, PBMCs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1 Infected subject previously included in the Phase I Clinical Trial with Tat protein
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous participation to the phase I clinical trial ISS T-001
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriano Lazzarin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Raffaele Hospital - Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aldo Di Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S. Gallicano Hospital- Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pasquale Narciso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.R.C.C.S. Spallanzani Hospital, Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Spallanzani Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Gallicano Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.hiv1tat-vaccines.info</url>
  </link>
  <link>
    <url>http://www.iss.it/aids/</url>
  </link>
  <reference>
    <citation>Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990 May 3;345(6270):84-6.</citation>
    <PMID>2184372</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993 Jan;67(1):277-87.</citation>
    <PMID>8416373</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994 Oct 20;371(6499):674-80.</citation>
    <PMID>7935812</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Buttò S, Monini P, Magnani M, Caputo A, Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS. 2006 Nov 28;20(18):2245-61. Review.</citation>
    <PMID>17117011</PMID>
  </reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Barbara Ensoli</name_title>
    <organization>CNAIDS - Istituto Superiore di Sanita</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Tat protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

